1. Metformin in Lung Cancer: Review of in Vitro and in Vivo Animal Studies
   Michael Yousef et al, 2017, Cancers CrossRef
2. Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic Drugs
   Panagiota Papanagnou et al, 2016, Pharmaceuticals CrossRef
3. The enhancement of combination of berberine and metformin in inhibition of DNMT1 gene expression through interplay of SP1 and PDPK1
   Fang Zheng et al, 2017, J. Cell. Mol. Med. CrossRef
4. null
   Fernando Peláez et al, 2017 CrossRef
5. Metformin inhibits the development, and promotes the resensitization, of treatment-resistant breast cancer
   Gerald Davies et al, 2017, PLoS ONE CrossRef
6. Metformin and caffeic acid regulate metabolic reprogramming in human cervical carcinoma SiHa/HTB-35 cells and augment anticancer activity of Cisplatin via cell cycle regulation
   Malgorzata Tyszka-Czochara et al, 2017, Food and Chemical Toxicology CrossRef
7. Antitumor effects of metformin are a result of inhibiting nuclear factor kappa B nuclear translocation in esophageal squamous cell carcinoma
   Nobufumi Sekino et al, 2018, Cancer Sci CrossRef
8. Formononetin and metformin act synergistically to inhibit growth of MCF-7 breast cancer cells in vitro
   Min Xin et al, 2019, Biomedicine & Pharmacotherapy CrossRef
9. Diabetes mellitus and survival of non-small cell lung cancer patients after surgery: A comprehensive systematic review and meta-analysis
   Han-Yu Deng et al, 2019, Thorac Cancer CrossRef
10. Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor–Mutated Lung Adenocarcinoma
    Oscar Arrieta et al, 2019, JAMA Oncol CrossRef
11. Metformin therapy and the risk of colorectal adenoma in patients with type 2 diabetes: A meta-analysis
    Yi-Chao Hou et al, 2017, Oncotarget CrossRef
12. Metformin and lung cancer risk in patients with type 2 diabetes mellitus
    Chin-Hsiao Tseng, 2017, Oncotarget CrossRef
13. Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy: translational biology and rationale for current clinical trials
    Michael Troncone et al, 2017, Oncotarget CrossRef
14. Metformin requires 4E-BPs to induce apoptosis and repress translation of Mcl-1 in hepatocellular carcinoma cells
    Mamatha Bhat et al, 2017, Oncotarget CrossRef
15. The regulatory role of aberrant Phosphatase and Tensin Homologue and Liver Kinase B1 on AKT/mTOR/c-Myc axis in pancreatic neuroendocrine tumors
    Tsung-Ming Chang et al, 2017, Oncotarget CrossRef
16. Glucose 6-phosphate dehydrogenase inhibition sensitizes melanoma cells to metformin treatment
    María Florencia Arbe et al, 2020, Translational Oncology CrossRef
17. null
    Hsuen-Wen Kate Chang et al, 2020 CrossRef
18. Molecular mechanisms underlining the role of metformin as a therapeutic agent in lung cancer.
    Ali Fatehi Hassanabad et al, 2021, Cell Oncol (Dordr) CrossRef
19. Effect of Metformin in Preventing Insulin-Mediated Proliferation of p53 and Liver Kinase B1 Mutant and Wild-Type Lung Cancer Cell Lines
    Manu Krishnan et al, 2018 CrossRef
20. Metformin Attenuates Silica-Induced Pulmonary Fibrosis by Activating Autophagy via the AMPK-mTOR Signaling Pathway
    Shu-xian Li et al, 2021, Front. Pharmacol. CrossRef
21. Metformin inhibits gastric cancer cell proliferation by regulation of a novel Loc100506691-CHAC1 axis.
    Hui-Hwa Tseng et al, 2021, Mol Ther Oncolytics CrossRef
22. EVT‐701 is a novel selective and safe mitochondrial complex 1 inhibitor with potent anti‐tumor activity in models of solid cancers
    Raquel Luna Yolba et al, 2021, Pharmacol Res Perspect CrossRef
23. Caffeic acid, a dietary polyphenol, as a promising candidate for combination therapy
    Swastika Maity et al, 2021, Chem. Pap. CrossRef
24. Metformin Treatment or PRODH/POX-Knock out Similarly Induces Apoptosis by Reprograming of Amino Acid Metabolism, TCA, Urea Cycle and Pentose Phosphate Pathway in MCF-7 Breast Cancer Cells
    Thi Yen Ly Huynh et al, 2021, Biomolecules CrossRef
25. Proline Dehydrogenase/Proline Oxidase (PRODH/POX) Is Involved in the Mechanism of Metformin-Induced Apoptosis in C32 Melanoma Cell Line
    Ilona Oscilowska et al, 2022, IJMS CrossRef
26. Metformin Enhances TKI-Afatinib Cytotoxic Effect, Causing Downregulation of Glycolysis, Epithelial–Mesenchymal Transition, and EGFR-Signaling Pathway Activation in Lung Cancer Cells
    Pedro Barrios-Bernal et al, 2022, Pharmaceuticals CrossRef
27. Metformin Induces PRODH/POX-Dependent Apoptosis in Breast Cancer Cells
    Thi Yen Ly Huynh et al, 2022, Front. Mol. Biosci. CrossRef
28. Will We Unlock the Benefit of Metformin for Patients with Lung Cancer? Lessons from Current Evidence and New Hypotheses
    Pedro Barrios-Bernal et al, 2022, Pharmaceuticals CrossRef
29. Are STK11 polymorphisms a predictor of the response to metformin in polycystic ovarian syndrome?
    Jehan Hamadneh et al, 2022, Biomed Rep CrossRef
30. The role of metformin in the treatment of non-small cell lung cancer
    Jelena Ljubičić et al, 2022, Zdravstvena zaštita CrossRef
31. Low-Dose Metformin Treatment Reduces In Vitro Growth of the LL/2 Non-small Cell Lung Cancer Cell Line
    Nicole L. Stott Bond et al, 2022, Biomedicines CrossRef
32. The effect of metformin on viability and mitochondrial status of tumor and non-tumor cell line
    Jelena Ljubičić et al, 2022, Medicinski podmladak CrossRef
33. A Novel Combination of Sotorasib and Metformin Enhances Cytotoxicity and Apoptosis in KRAS-Mutated Non-Small Cell Lung Cancer Cell Lines through MAPK and P70S6K Inhibition
    Pedro Barrios-Bernal et al, 2023, IJMS CrossRef
34. Dietary Folate Deficiency Promotes Lactate Metabolic Disorders to Sensitize Lung Cancer Metastasis through MTOR-Signaling-Mediated Druggable Oncotargets
    Wan-Jing Chen et al, 2023, Nutrients CrossRef
35. Efficacy of metformin adjunctive therapy as the treatment for non-diabetic patients with advanced non-small cell lung cancer: A Systematic review and Meta-analysis
    Xueyu Duan et al, 2023, J Res Med Sci CrossRef
36. Low BMI patients with advanced EGFR mutation-positive NSCLC can get a better outcome from metformin plus EGFR-TKI as first-line therapy: A secondary analysis of a phase 2 randomized clinical trial
    Rui Han et al, 2023, Chinese Medical Journal Pulmonary and Critical Care Medicine CrossRef
37. Enhancing the anticancer potential of Metformin: Fabrication of efficient nanospanlastics, in vitro cytotoxic studies on HEP-2 cells and reactome enhanced pathway analysis
    Shereen Nader Raafat et al, 2023, International Journal of Pharmaceutics: X CrossRef